S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IIISupportive care, TreatmentClosed18 to 49NCI, OtherCDR0000327758
S0230, CALGB-40401, IBCSG-34-05, U10CA037429, SWOG-S0230, ECOG-S0230, EUDRACT-2006-002600-33, EU-20632, NCT00068601

Trial Description


RATIONALE: Goserelin blocks hormone production in the ovaries. It is not yet known whether ovarian suppression using goserelin will prevent ovarian failure (early menopause) in women receiving chemotherapy for breast cancer.

PURPOSE: This randomized phase III trial is studying how well giving goserelin together with chemotherapy works compared with chemotherapy alone in preventing early menopause in women with stage I, stage II, or stage IIIA breast cancer.

Further Study Information



  • Compare the rate of premature ovarian failure in women with stage I-IIIA hormone receptor-negative breast cancer treated with chemotherapy with vs without goserelin.


  • Compare the rate of ovarian dysfunction in patients treated with these regimens.
  • Compare ovarian reserve in patients treated with these regimens.
  • Describe the pregnancy rates in patients treated with these regimens.

OUTLINE: This is a randomized study. Patients are stratified according to age (under 40 vs 40 to 49) and planned chemotherapy regimen (3- to 4-month/course anthracycline-based vs 6- to 8-month/course anthracycline-based vs 3- to 4-month/course non-anthracycline-based vs 6- to 8-month/course non-anthracycline-based). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive goserelin subcutaneously once every 4 weeks beginning 1 week before start of cyclophosphamide-containing chemotherapy. Treatment continues until completion of chemotherapy in the absence of disease progression or unacceptable toxicity.
  • Arm II: Patients receive cyclophosphamide-containing chemotherapy alone. Patients are followed at 1, 2, and 5 years.

PROJECTED ACCRUAL: A total of 416 patients (208 per treatment arm) will be accrued for this study within 3 years.

Eligibility Criteria


  • Histologically confirmed invasive breast cancer
  • Stage I-IIIA
  • Operable disease
  • Bilateral synchronous invasive breast cancer allowed provided primary tumors were diagnosed no more than 1 month apart and both tumors are hormone receptor negative
  • Must be planning to receive 3-8 months of a preoperative or postoperative chemotherapy regimen containing alkylating agents (anthracyclines or non-anthracyclines), meeting 1 of the following criteria:
  • 3-month/4-course anthracycline-based regimen
  • 6- to 8-month/course anthracycline-based regimen
  • 6- to 8-month/course non-anthracycline-based regimen
  • Hormone receptor status:
  • Estrogen receptor negative
  • Progesterone receptor negative



  • 18 to 49


  • Female

Menopausal status

  • Premenopausal

Performance status

  • Zubrod 0-2

Life expectancy

  • Not specified


  • Not specified


  • Not specified


  • Not specified


  • Not pregnant or nursing
  • Fertile patients must use effective barrier contraception
  • No other prior malignancy except adequately treated basal cell or squamous cell skin cancer or any in situ cancer from which the patient has been disease-free for at least 5 years after treatment with curative intent


Biologic therapy

  • Not specified


  • See Disease Characteristics
  • No prior cytotoxic chemotherapy

Endocrine therapy

  • No other concurrent hormonal therapy


  • Concurrent radiotherapy to the breast, chest wall, or lymph nodes allowed


  • See Disease Characteristics


  • Concurrent participation in other therapeutic clinical trials, including SWOG-S0221, allowed

Trial Contact Information

Trial Lead Organizations/Sponsors

Southwest Oncology Group

  • National Cancer Institute
  • Cancer and Leukemia Group B
  • Eastern Cooperative Oncology Group
  • International Breast Cancer Study Group
Halle C Moore, MD, Principal Investigator
Kathy S. Albain, Study Chair
Silvana Martino, Study Chair
Ann Hart Partridge, Study Chair
Lori J. Goldstein, Study Chair
Kelly-Anne Phillips, Study Chair

Link to the current ClinicalTrials.gov record.
NLM Identifier NCT00068601
ClinicalTrials.gov processed this data on April 09, 2015

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.